Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group).
multicenter cohort study
pelvic lymph node dissection
prostate cancer
robot-assisted radical prostatectomy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Nov 2022
25 Nov 2022
Historique:
received:
17
10
2022
revised:
18
11
2022
accepted:
24
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
In this multicenter retrospective cohort study, we aimed to evaluate whether pelvic lymph node dissection (PLND) improved biochemical recurrence (BCR) in patients with prostate cancer (PCa) who underwent robot-assisted radical prostatectomy (RARP) in Japan. A multicenter retrospective cohort study of 3195 PCa patients undergoing RARP at nine institutions in Japan was conducted. Enrolled patients were divided into two groups: those who underwent RARP without PLND (non-PLND group) and those who underwent PLND (PLND group). The primary endpoint was biochemical recurrence-free survival (BRFS) in PCa patients who underwent PLND. We developed a propensity score analysis to reduce the effects of selection bias and potential confounding factors. Propensity score matching resulted in 1210 patients being enrolled in the study. The 2-year BRFS rate was 95.0% for all patients, 95.8% for the non-PLND group, and 94.3% for the PLND group (
Identifiants
pubmed: 36497284
pii: cancers14235803
doi: 10.3390/cancers14235803
pmc: PMC9740735
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Curr Urol Rep. 2017 Jul;18(7):51
pubmed: 28589397
Eur Urol. 2009 Jun;55(6):1251-65
pubmed: 19297079
BJU Int. 2011 Jul;108(2):209-16
pubmed: 21044247
Mol Clin Oncol. 2017 May;6(5):775-781
pubmed: 28515930
J Urol. 2020 Feb;203(2):338-343
pubmed: 31437119
Eur Urol. 2015 Feb;67(2):212-9
pubmed: 24882672
Eur Urol. 2017 Jul;72(1):84-109
pubmed: 28126351
Urol Oncol. 2015 May;33(5):208-16
pubmed: 25547974
Urology. 2013 Sep;82(3):653-8
pubmed: 23987158
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
J Urol. 2022 Jul;208(1):19-25
pubmed: 35536148
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
Sci Rep. 2019 Nov 29;9(1):17985
pubmed: 31784574
Eur Urol Oncol. 2021 Aug;4(4):532-539
pubmed: 33865797
Urol Oncol. 2020 Nov;38(11):847.e9-847.e16
pubmed: 32466877
Cent European J Urol. 2018;71(3):262-269
pubmed: 30386645
CA Cancer J Clin. 2017 May 6;67(3):245-253
pubmed: 28222223
Urol Int. 2019;103(2):125-136
pubmed: 31039571
J Urol. 2003 Jan;169(1):145-7; discussion 147-8
pubmed: 12478123
Eur Urol. 2017 Feb;71(2):249-256
pubmed: 27209538
Prostate. 2018 May;78(6):419-425
pubmed: 29368339
Ann Surg Oncol. 2017 Jul;24(7):2047-2054
pubmed: 28271172
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2021 May;79(5):595-604
pubmed: 33293077
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Eur Urol Oncol. 2021 Apr;4(2):134-149
pubmed: 33745687
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Front Oncol. 2022 Jan 26;11:790183
pubmed: 35155191